Nurix Therapeutics Inc. (NRIX): Price and Financial Metrics


Nurix Therapeutics Inc. (NRIX): $13.32

0.65 (+5.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NRIX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NRIX POWR Grades


  • NRIX scores best on the Value dimension, with a Value rank ahead of 66% of US stocks.
  • NRIX's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • NRIX's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

NRIX Stock Summary

  • Nurix Therapeutics Inc's stock had its IPO on July 24, 2020, making it an older stock than merely 3.92% of US equities in our set.
  • Of note is the ratio of Nurix Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 8.43% of US stocks have a lower such ratio.
  • NRIX's price/sales ratio is 22.44; that's higher than the P/S ratio of 93.49% of US stocks.
  • Stocks that are quantitatively similar to NRIX, based on their financial statements, market capitalization, and price volatility, are SGMO, XENE, CNCE, PTGX, and BPMC.
  • NRIX's SEC filings can be seen here. And to visit Nurix Therapeutics Inc's official web site, go to www.nurixtx.com.

NRIX Valuation Summary

  • In comparison to the median Healthcare stock, NRIX's price/earnings ratio is 144.11% lower, now standing at -16.1.
  • Over the past 13 months, NRIX's price/earnings ratio has gone up 16.3.
  • NRIX's price/earnings ratio has moved up 16.3 over the prior 13 months.

Below are key valuation metrics over time for NRIX.

Stock Date P/S P/B P/E EV/EBIT
NRIX 2021-08-31 62.5 3.6 -16.1 -14.0
NRIX 2021-08-30 64.9 3.7 -16.7 -14.6
NRIX 2021-08-27 62.4 3.6 -16.0 -14.0
NRIX 2021-08-26 60.4 3.5 -15.5 -13.4
NRIX 2021-08-25 59.6 3.4 -15.3 -13.2
NRIX 2021-08-24 60.5 3.5 -15.5 -13.5

NRIX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NRIX has a Quality Grade of D, ranking ahead of 10.83% of graded US stocks.
  • NRIX's asset turnover comes in at 0.064 -- ranking 303rd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows NRIX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-08-31 0.064 1 -0.385
2021-05-31 0.053 1 -0.422
2020-11-30 0.081 1 -0.566

NRIX Price Target

For more insight on analysts targets of NRIX, see our NRIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $49.17 Average Broker Recommendation 1.36 (Strong Buy)

NRIX Stock Price Chart Interactive Chart >

Price chart for NRIX

NRIX Price/Volume Stats

Current price $13.32 52-week high $37.42
Prev. close $12.67 52-week low $7.52
Day low $12.64 Volume 508,500
Day high $13.61 Avg. volume 505,417
50-day MA $10.77 Dividend yield N/A
200-day MA $20.62 Market Cap 598.73M

Nurix Therapeutics Inc. (NRIX) Company Bio


Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.


NRIX Latest News Stream


Event/Time News Detail
Loading, please wait...

NRIX Latest Social Stream


Loading social stream, please wait...

View Full NRIX Social Stream

Latest NRIX News From Around the Web

Below are the latest news stories about Nurix Therapeutics Inc that investors may wish to consider to help them evaluate NRIX as an investment opportunity.

Cathie Wood’s Latest Portfolio: 10 New Stock Picks

In this article, we discuss the 10 new stocks that Cathie Wood added to her portfolio in Q4 2021. You can skip our comprehensive analysis of ARK Investment Management’s investment strategy, and go directly to Cathie Wood’s Latest Portfolio: 5 New Stock Picks. Cathie Wood is the CEO, CIO, and founder of ARK Investment Management. Starting […]

Yahoo | February 18, 2022

Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 PM ET. The event will be webcast live and may be accessed via a link in the Investors section of the Nu

Yahoo | February 10, 2022

Berenberg Bank Thinks Nurix Therapeutics’ Stock is Going to Recover

In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $48.00. The company's shares closed last Thursday at $17.29, close to its 52-week low of $17.10. According to TipRanks.com, Shu is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.9% and a 14.4% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nurix Therapeutics with a $51.

Howard Kim on TipRanks | January 28, 2022

Nurix Therapeutics (NRIX) Receives a Buy from Needham

In a report released today, Gil Blum from Needham maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $48.00. The company's shares closed last Thursday at $17.29, close to its 52-week low of $17.10. According to TipRanks.com, Blum 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -44.3% and a 5.5% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Crispr Therapeutics AG. Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $49.75, implying a 168.

Brian Anderson on TipRanks | January 28, 2022

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -26.87% and 50.67%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | January 27, 2022

Read More 'NRIX' Stories Here

NRIX Price Returns

1-mo 26.02%
3-mo -3.62%
6-mo -51.69%
1-year N/A
3-year N/A
5-year N/A
YTD -53.99%
2021 -11.95%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4179 seconds.